Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Govorestat (AT-007) in Healthy Adults and Adults with Classic Galactosemia
NCT04117711Phase 2Completed
- Sponsor
- Applied Therapeutics, Inc.
- Start
- Jun 2019
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of govorestat in Classic Galactosemia (GALT) (4 arms), sponsored by Applied Therapeutics, Inc. Primary endpoint: Treatment-emergent Adverse Events at 90 days. Started Jun 2019; status: completed.
02
Drugs
govorestat
03
Conditions
Classic Galactosemia (GALT)
Beyond the preview
Go deeper on NCT04117711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04117711.